

# Herantis Pharma: Invitation to Full Year 2023 results webcast on March 6, 2024

Herantis Pharma Plc | Press Release | February 19, 2024 at 10:00:00 EET

**Herantis Pharma Plc ("Herantis")**, a clinical-stage biotechnology company developing disease modifying therapies for Parkinson's disease will webcast 2H and FY 2023 results, **Wednesday March 6 at 9:30 am EET (8:30 CET)**. The presentation will be held by CEO Antti Vuolanto and CFO Tone Kvåle, followed by a Q&A session.

Herantis will release 2H and FY 2023 Report on March 6 at 8:00 am EET (7:00 CET). The report and presentation materials will be made available online at [www.herantis.com](http://www.herantis.com).

Please use the following link to register for this event:

<https://herantis.videosync.fi/fy-2023-report>

After registering, you will receive a confirmation email containing information about joining the webcast. Questions can be submitted throughout the webcast event.

Following the webcast of the live call, a recording will be available on Herantis Pharma's website:

<https://herantis.com/news-events/video-presentations/>

For more information, please contact:

Tone Kvåle, CFO

Tel: +47 915 19576

Email: [ir@herantis.com](mailto:ir@herantis.com)

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225

About Herantis Pharma Plc

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson's disease. Herantis' lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDFN protein. It combines the compelling mechanism of action of CDFN with the convenience of subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Company website: [www.herantis.com](http://www.herantis.com)

Press Release  
19 February 2024 10:00:00 EET

---

**HERANTIS**  
PHARMA

**Attachments**

[Herantis Pharma: Invitation to Full Year 2023 results webcast on March 6, 2024](#)